GO:0008481 sphingosine kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008481 (sphingosine kinase activity) catalyzes the phosphorylation of a sphingoid base by ATP to form a sphingoid 1-phosphate, ADP and H+.
• The two principal human enzymes are SPHK1 and SPHK2, which differ in tissue distribution, subcellular localization and substrate preference.
• Sphingosine kinase activity is a central node in sphingolipid metabolism, controlling the balance between pro-apoptotic ceramide/sphingosine and pro-survival sphingosine-1-phosphate (S1P).
• SPHK1 and SPHK2 are implicated in cancer, liver fibrosis, cardioprotection and metabolic disease, making them attractive drug targets.
• Sphingosine kinase activity can be measured by capillary electrophoresis with fluorescent sphingosine, and by standard radiometric or mass-spectrometry assays.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to dissect isoform-specific functions of SPHK1 and SPHK2 in disease.
Description
Sphingosine kinase activity (GO:0008481) is a molecular function that phosphorylates sphingoid bases, most notably sphingosine and sphinganine, using ATP as the phosphate donor to generate sphingoid 1-phosphates, ADP and a proton. This reaction is the rate-limiting step in the production of sphingosine-1-phosphate (S1P), a potent bioactive lipid that regulates cell proliferation, migration, survival and immune cell trafficking. Because the balance between ceramide/sphingosine and S1P determines cell fate, sphingosine kinase activity sits at the interface of pro-apoptotic and pro-survival signaling. Researchers study this activity to understand how lipid signaling contributes to cancer, fibrosis, cardiovascular disease and metabolic disorders. The two canonical isoforms, SPHK1 and SPHK2, are encoded by distinct genes and exhibit different subcellular localizations and regulatory mechanisms. SPHK1 is predominantly cytosolic and translocates to the plasma membrane upon activation, whereas SPHK2 is found in the nucleus, mitochondria and endoplasmic reticulum. This spatial separation allows the two enzymes to produce S1P in distinct compartments, influencing different downstream pathways. Recent work has shown that SPHK2 regulates very-low-density lipoprotein (VLDL) secretion through mTORC2 and chaperone-mediated autophagy, highlighting its role in hepatic lipid metabolism. In parallel, SPHK1 in hepatic stellate cells potentiates liver fibrosis, and its inducible expression correlates with disease progression. Pharmacological inhibition of sphingosine kinase activity has demonstrated antitumor activity in preclinical models, underscoring its therapeutic potential. Thus, GO:0008481 is not merely a biochemical annotation but a central node in lipid signaling with broad physiological and pathological relevance.
sphingosine kinase activity At A Glance
| GO ID | GO:0008481 |
|---|---|
| GO term | sphingosine kinase activity |
| Ontology | molecular_function |
| Synonym | ATP:sphinganine 1-phosphotransferase activity; dihydrosphingosine kinase activity; dihydrosphingosine kinase (phosphorylating); sphinganine kinase activity; sphingosine kinase (phosphorylating) |
| Major function | Phosphorylation of sphingoid bases (e.g., sphingosine, sphinganine) using ATP to produce sphingoid 1-phosphates, ADP and H+ |
| Major enzymes | SPHK1, SPHK2 |
| Substrates | Sphingosine, dihydrosphingosine (sphinganine), ATP |
| Products | Sphingosine-1-phosphate, dihydrosphingosine-1-phosphate, ADP, H+ |
| Cofactors | Mg2+ (magnesium ion) |
| Subcellular localization | Cytosol, plasma membrane, nucleus, mitochondria, endoplasmic reticulum (isoform-dependent) |
What Is GO:0008481?
According to the Gene Ontology, GO:0008481 (sphingosine kinase activity) is defined as the catalysis of the reaction: a sphingoid base + ATP = a sphingoid 1-phosphate + ADP + H+. In practical terms, this activity transfers a phosphate group from ATP to the hydroxyl group at the first carbon of a sphingoid base, such as sphingosine or sphinganine (dihydrosphingosine), yielding the corresponding 1-phosphate and releasing ADP and a proton. The term encompasses several synonymous activities, including ATP:sphinganine 1-phosphotransferase activity, dihydrosphingosine kinase activity, sphinganine kinase activity, and sphingosine kinase (phosphorylating) activity. These synonyms reflect the historical discovery of the enzyme using different sphingoid substrates, but all refer to the same catalytic function. The reaction is magnesium-dependent and requires ATP as the phosphate donor. The products, sphingosine-1-phosphate (S1P) and dihydrosphingosine-1-phosphate, are bioactive lipids that can act intracellularly or be secreted to activate G-protein-coupled receptors. Because the reaction is reversible in vitro under certain conditions, the equilibrium favors product formation in vivo due to rapid downstream metabolism of S1P. The activity is measured in vitro using fluorescent or radiolabeled sphingosine substrates, and more recently by capillary electrophoresis, which allows precise determination of SPHK2 activity.
Why Is sphingosine kinase activity Important in Cell Biology?
Sphingosine kinase activity is critically important because it governs the production of sphingosine-1-phosphate (S1P), a lipid mediator that controls fundamental cellular processes such as proliferation, survival, migration and immune cell egress. Dysregulation of this activity is linked to numerous human diseases, including cancer, liver fibrosis, cardiovascular disorders and metabolic syndrome. The two isoforms, SPHK1 and SPHK2, often have opposing or non-redundant functions, and their specific roles are context-dependent. For example, SPHK2 deficiency impairs VLDL secretion by inhibiting mTORC2 phosphorylation and activating chaperone-mediated autophagy, revealing a role in hepatic lipid homeostasis. SPHK2 also regulates aryl hydrocarbon receptor nuclear translocation and target gene activation, connecting sphingolipid metabolism to xenobiotic responses. In hepatic stellate cells, inducible SPHK1 potentiates liver fibrosis, suggesting that isoform-specific inhibitors could be therapeutic. Pharmacological inhibition of sphingosine kinase activity has shown antitumor activity in preclinical models, validating it as a drug target. Moreover, sphingosine kinase regulation is involved in cardioprotection, where SPHK1 activation protects against ischemia-reperfusion injury. In osteosarcoma under tumor acidosis, S1P promotes FOS activation, linking sphingosine kinase activity to bone cancer progression. Therefore, understanding GO:0008481 is essential for both basic cell biology and translational research.
• Controls the balance between pro-apoptotic ceramide/sphingosine and pro-survival S1P, influencing cell fate.
• Implicated in cancer progression, including osteosarcoma, where S1P promotes FOS activation under acidosis.
• Plays a key role in liver fibrosis via inducible SPHK1 in hepatic stellate cells.
• Regulates hepatic VLDL secretion through SPHK2, mTORC2 and chaperone-mediated autophagy.
• Modulates aryl hydrocarbon receptor nuclear translocation and target gene activation via SPHK2.
• Involved in cardioprotection, with SPHK1 activation protecting against ischemia-reperfusion injury.
• Serves as a therapeutic target; sphingosine kinase inhibitors show antitumor activity.
• Provides a biochemical node for drug discovery in inflammation, fibrosis and metabolic disease.
• Essential for S1P gradient formation that guides immune cell trafficking.
• Offers isoform-specific functions that can be dissected using CRISPR models.
What Happens During sphingosine kinase activity?
Substrate binding and ATP coordination
In simple terms: The enzyme grabs its two starting materials: a sphingoid base and an ATP molecule.
Sphingosine kinase binds a sphingoid base, typically sphingosine or sphinganine (dihydrosphingosine), and ATP in a magnesium-dependent manner. The enzyme contains a conserved ATP-binding motif and a catalytic aspartate residue that coordinates the phosphate transfer. Structural studies of SPHK1 and SPHK2 have revealed a lipid-binding pocket that accommodates the sphingoid base with its long hydrocarbon chain and a polar headgroup. The binding of ATP is stabilized by Mg2+, which neutralizes the negative charges of the phosphate groups. This initial binding step is highly specific for sphingoid bases; other lipids such as ceramide are not substrates.
Phosphoryl transfer and product formation
In simple terms: The enzyme moves a phosphate from ATP onto the sphingoid base, creating sphingosine-1-phosphate.
Once substrates are bound, the catalytic aspartate abstracts a proton from the hydroxyl group of the sphingoid base, facilitating nucleophilic attack on the gamma-phosphate of ATP. This results in the transfer of the phosphate group to the C1 hydroxyl, forming sphingoid 1-phosphate, and the release of ADP and a proton. The reaction is rapid and essentially irreversible under physiological conditions because the product S1P is rapidly metabolized or exported. The formation of S1P is the rate-limiting step in S1P biosynthesis, making this activity a key control point. In vitro, the reaction can be measured using fluorescent sphingosine and capillary electrophoresis, which separates and quantifies the product.
Isoform-specific subcellular reactions
In simple terms: SPHK1 and SPHK2 work in different parts of the cell, producing S1P for different purposes.
SPHK1 is primarily cytosolic and translocates to the plasma membrane upon phosphorylation by ERK, where it accesses its substrate and produces S1P for export. In contrast, SPHK2 localizes to the nucleus, mitochondria and endoplasmic reticulum, where it can produce S1P that acts on intracellular targets or is secreted. For example, nuclear SPHK2 generates S1P that regulates histone acetylation and gene expression, while mitochondrial SPHK2 influences apoptosis. In the liver, SPHK2 in hepatocytes regulates VLDL secretion by modulating mTORC2 and chaperone-mediated autophagy. This spatial segregation allows the two isoforms to carry out non-redundant functions despite catalyzing the same biochemical reaction.
Regulation by phosphorylation and translocation
In simple terms: The enzyme can be turned on or off by adding phosphate tags or moving to different cell locations.
Sphingosine kinase activity is tightly regulated by post-translational modifications and protein-protein interactions. SPHK1 is activated by phosphorylation at Ser225 by ERK, which promotes its translocation to the plasma membrane and increases its catalytic activity. SPHK1 also interacts with TRAF2, which enhances its activity and stability. SPHK2 is regulated by phosphorylation and acetylation, and its nuclear localization is controlled by a nuclear localization signal. Additionally, SPHK2 activity can be modulated by interaction with mTORC2, as shown in VLDL secretion. These regulatory mechanisms ensure that S1P production is spatially and temporally controlled in response to extracellular stimuli.
Downstream signaling and feedback
In simple terms: The S1P made by the enzyme sends signals that affect cell behavior and can loop back to control the enzyme.
The product S1P can be secreted and bind to five G-protein-coupled receptors (S1PR1-5), activating downstream pathways such as PI3K/AKT, ERK and Rho GTPases. Intracellular S1P can also act on targets like HDAC1/2 and TRAF2, influencing gene expression and survival. In osteosarcoma under acidosis, S1P promotes FOS activation, contributing to tumor progression. Feedback regulation occurs through degradation of S1P by S1P phosphatases and lipid phosphate phosphatases, and through transcriptional regulation of SPHK1 and SPHK2. For instance, SPHK2 regulates aryl hydrocarbon receptor nuclear translocation, linking sphingolipid signaling to xenobiotic gene activation. This complex network underscores the importance of sphingosine kinase activity in cellular homeostasis.
Key Genes Involved in GO:0008481 sphingosine kinase activity
The following genes and proteins are directly involved in sphingosine kinase activity, either as catalytic enzymes, regulators or downstream effectors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPHK1 | Catalyzes phosphorylation of sphingosine to S1P; cytosolic, translocates to plasma membrane | Implicated in cancer, fibrosis, cardioprotection; target for inhibitors |
| SPHK2 | Catalyzes phosphorylation of sphingosine to S1P; nuclear, mitochondrial and ER localization | Regulates VLDL secretion, AhR signaling, apoptosis; potential drug target |
| S1PR1 | G-protein-coupled receptor for S1P; mediates cell migration and survival | Target in autoimmune and cardiovascular diseases |
| S1PR2 | G-protein-coupled receptor for S1P; can inhibit migration and promote fibrosis | Involved in liver fibrosis and cancer |
| S1PR3 | G-protein-coupled receptor for S1P; regulates vascular tone and inflammation | Studied in cardiovascular and inflammatory models |
| S1PR4 | G-protein-coupled receptor for S1P; expressed in immune cells | Role in immune cell trafficking |
| S1PR5 | G-protein-coupled receptor for S1P; expressed in CNS and NK cells | Studied in neuroinflammation |
| SPNS2 | S1P transporter; exports S1P from cells | Regulates S1P gradients in development and immunity |
| ABCC1 | ATP-binding cassette transporter; can export S1P | Contributes to S1P secretion in cancer |
| SGPL1 | S1P lyase; irreversibly degrades S1P | Controls S1P levels; mutations cause sphingosine-1-phosphate lyase insufficiency syndrome |
| SGPP1 | S1P phosphatase 1; dephosphorylates S1P | Regulates intracellular S1P levels |
| SGPP2 | S1P phosphatase 2; dephosphorylates S1P | Modulates S1P signaling |
| CERS1 | Ceramide synthase 1; produces ceramide from sphinganine | Balances sphingolipid flux |
| ASAH1 | Acid ceramidase; generates sphingosine from ceramide | Provides substrate for sphingosine kinase |
| DEGS1 | Dihydroceramide desaturase; converts dihydroceramide to ceramide | Affects sphingosine availability |
| TRAF2 | E3 ubiquitin ligase; interacts with SPHK1 to enhance activity | Regulates SPHK1 stability and signaling |
| ERK1/2 | Kinases that phosphorylate SPHK1 at Ser225 | Activate SPHK1 and promote translocation |
| mTORC2 | Kinase complex; regulated by SPHK2 in VLDL secretion | Links sphingolipid metabolism to autophagy and lipid secretion |
How Is sphingosine kinase activity Regulated?
Sphingosine kinase activity is regulated at multiple levels, including transcriptional control, post-translational modifications, protein-protein interactions and subcellular localization. SPHK1 is activated by phosphorylation at Ser225 by ERK1/2, which promotes its translocation to the plasma membrane and increases its catalytic activity. It also interacts with TRAF2, which enhances its activity and stability. SPHK2 is regulated by phosphorylation and acetylation, and its nuclear localization is controlled by a nuclear localization signal. Additionally, SPHK2 activity can be modulated by interaction with mTORC2, as shown in VLDL secretion. The expression of SPHK1 and SPHK2 is induced by various growth factors, cytokines and hypoxia, and can be downregulated by tumor suppressors. Feedback regulation occurs through degradation of S1P by S1P phosphatases and lipid phosphate phosphatases, and through transcriptional regulation of SPHK1 and SPHK2. For instance, SPHK2 regulates aryl hydrocarbon receptor nuclear translocation, linking sphingolipid signaling to xenobiotic gene activation. These regulatory mechanisms ensure that S1P production is spatially and temporally controlled in response to extracellular stimuli.
sphingosine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPHK1 | Liver fibrosis, cancer, cardioprotection | Hepatic stellate cell-specific inducible SPHK1 knockout mice |
| SPHK2 | VLDL secretion, AhR signaling, cancer | SPHK2 knockout hepatocytes and mouse models |
| SPHK1/SPHK2 | Osteosarcoma under acidosis | Osteosarcoma cell lines with SPHK1/2 knockout under acidic conditions |
| SPHK1 | Breast and colon cancer | Xenograft models with SPHK1 overexpression or knockout |
| SPHK2 | Neuroinflammation and multiple sclerosis | S1P receptor modulators in EAE models |
Sphingosine kinase activity in cancer
Sphingosine kinase activity is frequently elevated in human cancers, where it promotes cell proliferation, survival, migration and angiogenesis through S1P production. SPHK1 is overexpressed in many tumor types, including breast, colon, lung and prostate cancer, and its expression correlates with poor prognosis. Pharmacological inhibition of sphingosine kinase activity has demonstrated antitumor activity in preclinical models, reducing tumor growth and metastasis. In osteosarcoma under tumor acidosis, S1P promotes FOS activation, contributing to tumor progression. SPHK2 also plays a role in cancer; it can have pro-apoptotic or pro-survival effects depending on context, and its nuclear function regulates gene expression. Targeting sphingosine kinase activity is therefore a promising therapeutic strategy, with several inhibitors in clinical trials.
Sphingosine kinase activity in liver disease
Sphingosine kinase activity is critically involved in liver pathobiology, including fibrosis, steatosis and hepatocellular carcinoma. Inducible SPHK1 in hepatic stellate cells potentiates liver fibrosis, and its expression is upregulated in human fibrotic livers. SPHK2 deficiency impairs VLDL secretion by inhibiting mTORC2 phosphorylation and activating chaperone-mediated autophagy, linking sphingolipid metabolism to hepatic lipid homeostasis. These findings suggest that isoform-specific modulation of sphingosine kinase activity could be therapeutic for liver diseases.
Sphingosine kinase activity in cardiovascular disease
Sphingosine kinase activity plays a dual role in the cardiovascular system. SPHK1 activation is cardioprotective in ischemia-reperfusion injury, where S1P produced by SPHK1 reduces infarct size and improves cardiac function. However, excessive S1P signaling can contribute to vascular inflammation and atherosclerosis. The balance between SPHK1 and SPHK2 activities is important for maintaining vascular homeostasis. Targeting sphingosine kinase activity in cardiovascular disease requires careful isoform-specific approaches.
Sphingosine kinase activity in metabolic and immune disorders
Sphingosine kinase activity influences metabolic and immune disorders through S1P-mediated regulation of immune cell trafficking and insulin sensitivity. SPHK2 regulates aryl hydrocarbon receptor nuclear translocation and target gene activation, connecting sphingolipid metabolism to xenobiotic responses. In obesity and diabetes, altered sphingosine kinase activity contributes to insulin resistance and inflammation. S1P receptor modulators, such as fingolimod, are used to treat multiple sclerosis, highlighting the therapeutic relevance of this pathway. Thus, sphingosine kinase activity is a key node in metabolic and immune regulation.
From sphingosine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SPHK1 loss reduce liver fibrosis? | Hepatic stellate cell-specific SPHK1 knockout mice |
| How does SPHK2 regulate VLDL secretion? | SPHK2 knockout hepatocytes and liver-specific knockout mice |
| Does SPHK2 regulate AhR target genes? | SPHK2 knockout cell lines and AhR reporter assays |
| Can SPHK1 inhibition reduce tumor growth? | Xenograft models with SPHK1-overexpressing cancer cells treated with inhibitors |
| What is the role of SPHK1 phosphorylation at Ser225? | Point-mutation knock-in mice expressing SPHK1 S225A |
| How does S1P promote osteosarcoma under acidosis? | SPHK1/2 knockout osteosarcoma cells in acidic culture |
How to Study the sphingosine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiometric assay | Sphingosine kinase activity using [32P]ATP | Enzyme kinetics and inhibitor screening |
| Capillary electrophoresis | SPHK2 activity with fluorescent sphingosine | Isoform-specific activity determination |
| LC-MS/MS lipidomics | Sphingolipid species (ceramide, sphingosine, S1P) | Pathway flux and biomarker discovery |
| CRISPR knockout | Loss-of-function phenotypes | Isoform-specific function in disease models |
| Phosphoproteomics | Signaling changes downstream of SPHK1/2 | Identifying mTORC2 and AhR targets |
| RNA-seq | Transcriptional changes | AhR target gene activation |
| Conditional knockout mice | In vivo disease phenotypes | Liver fibrosis and VLDL secretion |
| Inhibitor treatment | Pharmacological inhibition of enzyme activity | Antitumor activity in xenografts |
Measuring sphingosine kinase activity
Sphingosine kinase activity can be measured using radiometric assays with [32P]ATP and sphingosine, followed by thin-layer chromatography or scintillation counting. More recently, capillary electrophoresis with fluorescent sphingosine has been developed for precise determination of SPHK2 activity. Mass spectrometry-based methods can quantify S1P and dihydro-S1P in biological samples, providing a direct readout of enzyme activity. These assays are essential for screening inhibitors and characterizing isoform-specific kinetics.
Genetic manipulation and CRISPR screens
CRISPR-Cas9 knockout of SPHK1 and SPHK2 is widely used to dissect their isoform-specific functions. Point mutations, such as S225A in SPHK1, can be introduced to study phosphorylation-dependent regulation. Knock-in of tagged SPHK1 or SPHK2 allows localization and interaction studies. Overexpression models are used to assess gain-of-function effects in cancer and fibrosis. CRISPR library screening can identify synthetic lethal interactions with sphingosine kinase activity.
Lipidomics and signaling analysis
Lipidomics using liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantifies sphingolipid species, including ceramide, sphingosine and S1P, providing a comprehensive view of pathway flux. Phosphoproteomics can identify downstream signaling changes upon SPHK1/2 manipulation. These methods are complemented by transcriptomics (RNA-seq) to assess gene expression changes, such as AhR target genes.
In vivo models and disease phenotyping
Mouse models with conditional knockout or transgenic overexpression of SPHK1 and SPHK2 are used to study disease phenotypes, including liver fibrosis, cancer and cardiovascular injury. For example, hepatic stellate cell-specific SPHK1 knockout mice show reduced fibrosis. SPHK2 knockout mice exhibit impaired VLDL secretion. These models are essential for validating therapeutic targets and understanding isoform-specific roles in vivo.
How CRISPR Can Be Used to Study GO:0008481 sphingosine kinase activity
Knockout
CRISPR-Cas9 knockout of SPHK1 or SPHK2 is used to eliminate enzyme activity and study loss-of-function phenotypes. For example, SPHK2 knockout in hepatocytes impairs VLDL secretion and activates chaperone-mediated autophagy. SPHK1 knockout in hepatic stellate cells reduces liver fibrosis. These models are essential for validating isoform-specific roles and identifying compensatory mechanisms.
Point Mutation
Point mutations, such as S225A in SPHK1, can be introduced via CRISPR to study phosphorylation-dependent regulation and catalytic activity. Catalytic dead mutants (e.g., D81A) are used to separate enzymatic activity from scaffolding functions. These models help dissect the contribution of sphingosine kinase activity to downstream signaling.
Knock-in
Knock-in of epitope-tagged SPHK1 or SPHK2 (e.g., FLAG, HA) allows for localization, interaction and activity studies in endogenous contexts. Knock-in of reporter genes (e.g., luciferase) under the SPHK1 promoter enables monitoring of expression in vivo. These models are valuable for understanding spatiotemporal regulation of sphingosine kinase activity.
Overexpression
Overexpression of SPHK1 or SPHK2 via CRISPR activation (CRISPRa) or lentiviral vectors is used to assess gain-of-function effects in cancer, fibrosis and metabolic disease. For instance, SPHK1 overexpression in hepatic stellate cells potentiates fibrosis. Overexpression models are also used to test the efficacy of sphingosine kinase inhibitors.
How EDITGENE Supports sphingosine kinase activity Research
Researchers studying sphingosine kinase activity-related genes often need to determine whether a candidate gene is causally involved in a specific disease or cellular process. This requires precise genetic models that can knockout, mutate, knock-in or overexpress the gene of interest in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such studies, from single-gene editing to high-throughput library screening.
Contact EDITGENE today to design your custom CRISPR model for sphingosine kinase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SPHK1 Knockout HEK293 Cell Line | EDJ-KQ1066 | Human | 8877 | Details Get a Quote |
| SPHK2 Knockout HEK293 Cell Line | EDJ-KQ1413 | Human | 56848 | Details Get a Quote |
| SPHK1 Knockout A-549 Cell Line | EDJ-KQ20196 | Human | 8877 | Details Get a Quote |
| SPHK1 Knockout HCT 116 Cell Line | EDJ-KQ20197 | Human | 8877 | Details Get a Quote |
| SPHK2 Knockout A-549 Cell Line | EDJ-KQ20951 | Human | 56848 | Details Get a Quote |
| SPHK2 Knockout HCT 116 Cell Line | EDJ-KQ20952 | Human | 56848 | Details Get a Quote |
| SPHK2 Knockout HeLa Cell Line | EDJ-KQ20953 | Human | 56848 | Details Get a Quote |
| SPHK1 Knockout HeLa Cell Line | EDJ-KQ18852 | Human | 8877 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
Frequently Asked Questions About sphingosine kinase activity
What is sphingosine kinase activity?
Sphingosine kinase activity (GO:0008481) is the enzymatic catalysis of the reaction: a sphingoid base + ATP = a sphingoid 1-phosphate + ADP + H+. It is the rate-limiting step in the production of sphingosine-1-phosphate (S1P), a bioactive lipid involved in cell survival, proliferation and migration.
What genes are involved in sphingosine kinase activity?
The two principal human genes are SPHK1 and SPHK2, which encode sphingosine kinase 1 and 2, respectively. Other related genes include S1P receptors (S1PR1-5), S1P transporters (SPNS2, ABCC1) and degradative enzymes (SGPL1, SGPP1, SGPP2).
What is the difference between SPHK1 and SPHK2?
SPHK1 is predominantly cytosolic and translocates to the plasma membrane upon activation, while SPHK2 localizes to the nucleus, mitochondria and endoplasmic reticulum. They have distinct substrate preferences, regulatory mechanisms and biological functions.
How is sphingosine kinase activity measured?
It can be measured using radiometric assays with [32P]ATP, capillary electrophoresis with fluorescent sphingosine, or mass spectrometry-based lipidomics to quantify S1P and related species.
What diseases are associated with sphingosine kinase activity?
Dysregulated sphingosine kinase activity is implicated in cancer, liver fibrosis, cardiovascular disease, metabolic disorders and immune-mediated diseases such as multiple sclerosis.
Can sphingosine kinase activity be inhibited therapeutically?
Yes, pharmacological inhibitors of sphingosine kinase have shown antitumor activity in preclinical models, and S1P receptor modulators are used clinically for multiple sclerosis.
What is the role of SPHK2 in liver metabolism?
SPHK2 deficiency impairs VLDL secretion by inhibiting mTORC2 phosphorylation and activating chaperone-mediated autophagy, linking sphingolipid metabolism to hepatic lipid homeostasis.
How does SPHK1 contribute to liver fibrosis?
Inducible SPHK1 in hepatic stellate cells potentiates liver fibrosis, and its expression is upregulated in human fibrotic livers, suggesting a therapeutic target.
What is the connection between sphingosine kinase activity and cancer?
Sphingosine kinase activity produces S1P, which promotes cancer cell proliferation, survival, migration and angiogenesis. SPHK1 is overexpressed in many cancers and correlates with poor prognosis.
What CRISPR models are available for studying sphingosine kinase activity?
EDITGENE offers CRISPR knockout, point mutation, knock-in and overexpression cell models for SPHK1, SPHK2 and related genes, as well as CRISPR library screening and bioinformatics services.
Conclusion
Sphingosine kinase activity (GO:0008481) is a fundamental enzymatic function that controls the production of sphingosine-1-phosphate, a lipid mediator with broad roles in cell survival, proliferation, migration and immune regulation. The two isoforms, SPHK1 and SPHK2, have distinct subcellular localizations and functions, and their dysregulation contributes to cancer, liver fibrosis, cardiovascular disease and metabolic disorders. Understanding the molecular mechanism, regulation and disease relevance of sphingosine kinase activity requires precise genetic models and robust biochemical assays. CRISPR-based knockout, point mutation, knock-in and overexpression models are indispensable for dissecting isoform-specific functions and validating therapeutic targets. EDITGENE provides comprehensive services to support such research, from custom cell model generation to high-throughput screening and bioinformatics analysis.
References
- 1. Zhang S et al.. 2025. Sphingosine kinase 2 deficiency impairs VLDL secretion by inhibiting mTORC2 phosphorylation and activating chaperone-mediated autophagy.. Cell Death Differ 32(10):1886-1899 PMID: 40200091
- 2. Yokoyama S et al.. 2024. Sphingosine Kinase 2 Regulates Aryl Hydrocarbon Receptor Nuclear Translocation and Target Gene Activation.. Adv Sci (Weinh) 11(40):e2400794 PMID: 39207053
- 3. Baek JS et al.. 2024. An inducible sphingosine kinase 1 in hepatic stellate cells potentiates liver fibrosis.. Biochem Pharmacol 229:116520 PMID: 39236934
- 4. Rohrbach T et al.. 2017. Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology.. Crit Rev Biochem Mol Biol 52(5):543-553 PMID: 28618839
- 5. French KJ et al.. 2006. Antitumor activity of sphingosine kinase inhibitors.. J Pharmacol Exp Ther 318(2):596-603 PMID: 16632640
- 6. Karliner JS. 2009. Sphingosine kinase regulation and cardioprotection.. Cardiovasc Res 82(2):184-92 PMID: 19017750
- 7. Bozzini N et al.. 2026. Sphingosine-1-Phosphate Promotes FOS Activation in Osteosarcoma Under Tumor Acidosis.. Acta Physiol (Oxf) 242(6):e70214 PMID: 42036820
- 8. Yangyuoru PM et al.. 2011. Determination of sphingosine kinase 2 activity using fluorescent sphingosine by capillary electrophoresis.. Electrophoresis 32(13):1742-9 PMID: 21706498
